MedTrace Logo

Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma

NCT04982211 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-07-29

No results posted yet for this study

Summary

The investigators propose to examine a mismatch-based method of reconsolidation blockade for the treatment of psychological trauma in military personnel and Federal police officers. The standard reconsolidation blockade treatment (aka Reconsolidation Therapy) involves reactivating the trauma memory while under the influence of propranolol. The mismatch method of Reconsolidation Therapy will involve varying the contexts in which the weekly trauma memory retrieval will occur. This study will involve 10 visits (eligibility assessment, treatments, and follow-up visits) over a 6-month period for each participant. Treatments will be conducted once a week for a six-week period where the participant will take a dose of propranolol (or a placebo pill) 60 minutes prior to memory reactivation. The investigators hypothesize that reconsolidation blockade treatment will be as effective in treating PTSD among military personnel and Federal police officers, with the mismatch condition showing greater symptom improvement.

Conditions

  • Trauma and Stressor Related Disorders
  • Post Traumatic Stress Disorder
  • Acute Stress Disorder
  • Adjustment Disorders

Interventions

DRUG

Propranolol

Oral propranolol hydrochloride capsules, dosed per participant weight

DRUG

Placebo

Oral placebo capsules, dosed per participant weight

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Douglas Mental Health University Institute

    lead OTHER

Principal Investigators

  • Alain Brunet, Ph.D. · Douglas Mental Health University Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982211 on ClinicalTrials.gov